A Multicenter, Open-Label, Safety Study of Meloxicam SoluMatrix Capsules in Subjects With Osteoarthritis of the Knee or Hip
Phase of Trial: Phase III
Latest Information Update: 30 Mar 2016
Price : $35 *
At a glance
- Drugs Meloxicam (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions; Registrational
- Sponsors Iroko Pharmaceuticals
- 30 Mar 2016 New analyses of data from this trial will be presented at the 2016 Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, according to an Iroko media release.
- 23 Oct 2015 According to an Iroko Pharmaceuticals media release, the NDA application to the US FDA include data from this trial.
- 12 Mar 2015 The US FDA accepted for review the NDA for SoluMatrix meloxicam, which was based on data from this trial and a phase III efficacy study, according to an Iroko Pharmaceuticals media release.